The trial would to try to establish:

• The best post-operative PPI prescription protocol after Sleeve Gastrectomy
• The impact of PPI therapy on postoperative peptic diseases (erosive gastropathies, ulcers, duodenitis, esophagitis and/or Barrett)
• The impact of PPI therapy on post-operative GERD symptoms (assessed with the use of two standard tests: MRGE-HRQL and GERDQ

45 patients candidate to primary SG and randomized in 3 study groups (15 per group) GROUP A: no treatment (control group)

GROUP B (standard dose-long term): Lansoprazole buccal tablets 30 mg once daily (before breakfast on an empty stomach) for 6 months

GROUP C (standard dose-short term): Lansoprazole buccal tablets 30 mg once daily (before breakfast on an empty stomach) for 3 months

Inclusion Criteria:

• Patients candidates for primary SG
• Patients adhering to the follow-up protocol
• Age between 18 and 65 years
• No BMI limits

Exclusion Criteria:

• Gastric and/or esophageal diseases (routine preoperative endoscopy)
• Patients candidate for revisional bariatric surgery
• Chronic preoperative PPI therapy
• Using of PPI treatment for postoperative complications
• Conversion to open surgery
• Patients allergic to PPI
• Patients undergoing concomitant surgery
• Patients with hiatal hernia undergoing concomitant cruroplasty